1. Home
  2. SILC vs IPHA Comparison

SILC vs IPHA Comparison

Compare SILC & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicom Ltd

SILC

Silicom Ltd

HOLD

Current Price

$42.89

Market Cap

163.8M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.42

Market Cap

131.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SILC
IPHA
Founded
1987
1999
Country
Israel
France
Employees
N/A
163
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.8M
131.4M
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
SILC
IPHA
Price
$42.89
$1.42
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
111.5K
21.0K
Earning Date
04-30-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.17
$180.36
Revenue Next Year
$12.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.34
$1.18
52 Week High
$48.92
$2.63

Technical Indicators

Market Signals
Indicator
SILC
IPHA
Relative Strength Index (RSI) 76.08 47.97
Support Level $16.10 $1.35
Resistance Level N/A $1.80
Average True Range (ATR) 3.72 0.08
MACD 1.00 -0.00
Stochastic Oscillator 78.30 31.82

Price Performance

Historical Comparison
SILC
IPHA

About SILC Silicom Ltd

Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: